Cantor Fitzgerald Maintains Overweight on Longboard Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has maintained an Overweight rating on Longboard Pharmaceuticals (LBPH) and increased the price target from $35 to $55.
January 02, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer reaffirms an Overweight rating on Longboard Pharmaceuticals and raises the price target to $55.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100